Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prurigo Nodularis Treatment Market

Prurigo Nodularis Treatment Market Share

Report ID: GMI3849
Published Date: Dec 2022
Report Format: PDF

Download Free Sample

Prurigo Nodularis Treatment Market Share

Major firms having a strong presence in the prurigo nodularis market are:

Teva Pharmaceutical Industries Ltd
Pfizer Inc
Sanofi
GlaxoSmithKline plc
Merck & Co Inc
Bayer AG
Johnson & Johnson Services Inc
Galderma Takeda Pharmaceuticals

Companies operating in this vertical are emphasizing developing novel treatment options for patients suffering from the given skin condition and making a mark in the healthcare sector.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for prurigo nodularis treatment garnered over USD 2 billion in 2022 and is poised to witness a 4% CAGR from 2023 to 2032 owing to the flourishing biotechnology and pharmaceutical sectors globally.

Corticosteroids segment is anticipated to accumulate more than 35.5% market share by 2032 due to the proven efficacy of corticosteroids in relieving the symptoms of prurigo nodularis.

Prurigo nodularis treatment market from the retail pharmacies segment amassed over USD 800 million in 2022 attributed to the increasing disease prevalence and wide range availability of a variety of medications at competitive prices.

Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co. Inc., Bayer AG, Johnson & Johnson Services Inc., Galderma, and Takeda Pharmaceuticals are the prominent companies operating in the market.